Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
ENB003 is an an antagonist that selectively binds to endothelin B receptor (ETBR) and inhibits downstream signaling, which potentially relieves tumor immunosuppression and inhibits proliferation of tumor cells expressing ETBR (Clin Cancer Res 2009;15(14):4521-4528; NCI Drug Dictionary).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|ENB003 + Pembrolizumab||ENB003 Pembrolizumab||0||1|